Acute pain management: the role of multimodal analgesia with a focus on dexketoprofen and tramadol hydrochloride fixed-dose combination in acute low back pain

Acute pain, such as moderate to severe low back pain, significantly impacts quality of life and is a leading cause of disability. Traditional pain management, often reliant on opioids, is facing scrutiny due to concerns about side effects, dependency and misuse. Multimodal analgesia, which combines different analgesics targeting various pain pathways, has emerged as a safer alternative to minimize opioid use. This narrative review focuses on the combination of dexketoprofen trometamol (a nonsteroidal anti-inflammatory drug) and tramadol hydrochloride (a centrally acting analgesic), which together target both peripheral and central pain mechanisms. Particular attention is given to the pharmacological properties of these agents and the results of key clinical trials, especially the Dexketoprofen TrometAmol aNd Tramadol HydrochloridE (DANTE) study. The DANTE study, a Phase IV clinical trial, demonstrated that the fixed-dose combination of dexketoprofen and tramadol significantly reduced pain intensity and improved functional outcomes in patients with acute low back pain. Furthermore, the combination showed a favorable safety profile comparable to that of single-agent treatments, with mild and manageable adverse events. This evidence suggests that the dexketoprofen–tramadol combination offers a more effective and well-tolerated alternative to traditional pain management strategies. By targeting multiple pain pathways simultaneously, this multimodal approach can enhance analgesic efficacy while reducing opioid reliance, representing a promising advance in the management of acute pain.

Acute pain; Multimodal analgesia; Dexketoprofen; Tramadol; Low back pain; DANTE study; Pain management; Pharmacological treatment

[1] Clarke H, Waisman A, Aternali A, Axenova K, Almohawis A, Curtis K, et al. Ten years of transitional pain service research and practice: where are we and where do we go from here? Regional Anesthesia and Pain Medicine. 2025; 50: e105609.

[2] Hanna M, Montero Matamala A, Perrot S, Varrassi G. Delivery of multimodal analgesia to effectively treat acute pain: a review from Roma pain days. Cureus. 2022; 14: e22465.

[3] Burke CA, Fillipo R, George SZ, Kapos FP, Kosinski AS, Ford E, et al. Transition from acute to chronic low back pain in a community-based cohort. The Journal of Pain. 2025; 26: 104704.

[4] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017; 390: 1211–1259.

[5] Varrassi G, Moretti B, Pace MC, Evangelista P, Iolascon G. Common clinical practice for low back pain treatment: a modified Delphi study. Pain and Therapy. 2021; 10: 589–604.

[6] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315: 1624–1645.

[7] Cher BAY, Morden NE, Meara E. Medicaid expansion and prescription trends: opioids, addiction therapies, and other drugs. Medical Care. 2019; 57: 208–212.

[8] Hanna M, Perrot S, Varrassi G. Critical appraisal of current acute LBP management and the role of a multimodal analgesia: a narrative review. Pain and Therapy. 2023; 12: 377–398.

[9] Taylor C, Metcalf A, Morales A, Lam J, Wilson R, Baribeault T. Multimodal analgesia and opioid-free anesthesia in spinal surgery: a literature review. Journal of Perianesthesia Nursing. 2023; 38: 938–942.

[10] Muñoz-Leyva F, Jack JM, Bhatia A, Chin KJ, Gandhi R, Perlas A, et al. No benefits of adding dexmedetomidine, ketamine, dexamethasone, and nerve blocks to an established multimodal analgesic regimen after total knee arthroplasty. Anesthesiology. 2022; 137: 459–470.

[11] Varrassi G, Hanna M, Coaccioli S, Fabrizzi P, Baldini S, Kruljac I, et al. Dexketoprofen trometamol and tramadol hydrochloride fixed-dose combination in moderate to severe acute low back pain: a phase IV, randomized, parallel group, placebo, active-controlled study (DANTE). Pain and Therapy. 2024; 13: 1007–1022.

[12] Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Research Integrity and Peer Review. 2019; 4: 5.

[13] Grau JW, Huang YJ, Turtle JD, Strain MM, Miranda RC, Garraway SM, et al. When pain hurts: nociceptive stimulation induces a state of maladaptive plasticity and impairs recovery after spinal cord injury. Journal of Neurotrauma. 2017; 34: 1873–1890.

[14] Chapman CR, Vierck CJ. The transition of acute postoperative pain to chronic pain: an integrative overview of research on mechanisms. The Journal of Pain. 2017; 18: 359.e1–359.e38.

[15] Asimakopoulos T, Tsaroucha A, Kouri M, Pasqualucci A, Varrassi G, Leoni MLG, et al. The role of biomarkers in acute pain: a narrative review. Pain and Therapy. 2025; 14: 775–789.

[16] Giglio M, Corriero A, Preziosa A, Varrassi G, Puntillo F. The putative role of immune-inflammatory mechanisms in nociplastic pain pathways: a narrative review. Exploration of Immunology. 2025; 5: 1003178.

[17] Santos MD, Oh KS, Varrassi G, Nagrale D. Multimodal analgesia for postoperative pain in Asia: a review of evidence with clinical focus on dexketoprofen and tramadol/dexketoprofen fixed-dose combination. Signa Vitae. 2021; 17: 1–7.

[18] Jensen MP, Castarlenas E, Tomé-Pires C, de la Vega R, Sánchez-Rodríguez E, Miró J. The number of ratings needed for valid pain assessment in clinical trials: replication and extension. Pain Medicine. 2015; 16: 1764–1772.

[19] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011; 152: S2–S15.

[20] Tagliaferri SD, Miller CT, Owen PJ, Mitchell UH, Brisby H, Fitzgibbon B, et al. Domains of chronic low back pain and assessing treatment effectiveness: a clinical perspective. Pain practice. 2020; 20: 211–225.

[21] Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis and Rheumatism. 2012; 64: 2028–2037.

[22] Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases. 2014; 73: 968–974.

[23] Manchikanti L, Singh V, Falco FJE, Benyamin RM, Hirsch JA. Epidemiology of low back pain in adults. Neuromodulation. 2014; 17: 3–10.

[24] Linton SJ, Shaw WS. Impact of psychological factors in the experience of pain. Physical Therapy. 2011; 91: 700–711.

[25] Parreira P, Maher CG, Steffens D, Hancock MJ, Ferreira ML. Risk factors for low back pain and sciatica: an umbrella review. The Spine Journal. 2018; 18: 1715–1721.

[26] Alammari MA, Alammari AA, Alammari AA, Alammari AA, Alammari NA, Ibrahim Alabdali MY. Psychosocial and occupational factors associated with low back pain among healthcare professionals: a systematic review. Cureus. 2025; 17: e77426.

[27] Floyd SB, NcGarby S, Cordero Romero S, Garrison S, Walker K, Hendry W, et al. Emergency department alternatives to opioids: adapting and implementing proven therapies in practice. International Journal of Environmental Research and Public Health. 2023; 20: 1206.

[28] Skolnick P. The opioid epidemic: crisis and solutions. Annual Review of Pharmacology and Toxicology. 2018; 58: 143–159.

[29] Helander EM, Menard BL, Harmon CM, Homra BK, Allain AV, Bordelon GJ, et al. Multimodal analgesia, current concepts, and acute pain considerations. Current Pain and Headache Reports. 2017; 21: 3.

[30] Pergolizzi J, Varrassi G, LeQuang JAK, Breve F, Magnusson P. Fixed dose versus loose dose: analgesic combinations. Cureus. 2023; 15: e33320.

[31] Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recommendations and Reports. 2022; 71: 1–95.

[32] Clark IC, Allman RD, Rogers AL, Goda TS, Smith K, Chanas T, et al. Multimodal pain management protocol to decrease opioid use and to improve pain control after thoracic surgery. The Annals of Thoracic Surgery. 2022; 114: 2008–2014.

[33] Shi Y, Wu W. Multimodal non-invasive non-pharmacological therapies for chronic pain: mechanisms and progress. BMC Medicine. 2023; 21: 372.

[34] Varrassi G, Pergolizzi JV, Dowling P, Paladini A. Ibuprofen safety at the golden anniversary: are all NSAIDs the same? A narrative review. Advances in Therapy. 2020; 37: 61–82.

[35] Pergolizzi JV, Magnusson P, LeQuang JA, Breve F, Taylor R, Wollmuth C, et al. Can NSAIDs and acetaminophen effectively replace opioid treatment options for acute pain? Expert Opinion on Pharmacotherapy. 2021; 22: 1119–1126.

[36] Rajan S, Rishi G, Ibrahim M. Opioid alternatives in spine surgeries. Current Opinion in Anaesthesiology. 2024; 37: 470–477.

[37] Michaelides A, Zis P. Depression, anxiety and acute pain: links and management challenges. Postgraduate Medicine. 2019; 131: 438–444.

[38] Rawal N. Current issues in postoperative pain management. European Journal of Anaesthesiology. 2016; 33: 160–171.

[39] Wewege MA, Bagg MK, Jones MD, Ferraro MC, Cashin AG, Rizzo RR, et al. Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis. The BMJ. 2023; 380: e072962.

[40] Nicholas TA, Robinson R. Multimodal analgesia in the era of the opioid epidemic. The Surgical Clinics of North America. 2022; 102: 105–115.

[41] McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews. 2013; 2013: CD006146.

[42] Mauleón D, Artigas R, García ML, Carganico G. Preclinical and clinical development of dexketoprofen. Drugs. 1996; 52: 24–45; discussion 45–46.

[43] Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003; 52: 600–608.

[44] Kuczyńska J, Pawlak A, Nieradko-Iwanicka B. The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021). Biomedicine & Pharmacotherapy. 2022; 149: 112819.

[45] Hanna M, Moon JY. A review of dexketoprofen trometamol in acute pain. Current Medical Research and Opinion. 2019; 35: 189–202.

[46] Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CWC, Chenot JF, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. European Spine Journal. 2018; 27: 2791–2803.

[47] Inage K, Sainoh T, Okuyama K, Yamashita M, Ohyama S, Fujimoto K, et al. The analgesic and side effects of tramadol hydrochloride immediate-release and extended-release tablets in patients with chronic low back pain. Cureus. 2024; 16: e72124.

[48] Vazzana M, Andreani T, Fangueiro J, Faggio C, Silva C, Santini A, et al. Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomedicine & Pharmacotherapy. 2015; 70: 234–238.

[49] Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesthesia and Analgesia. 2017; 124: 44–51.

[50] Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. The Journal of Pain. 2016; 17: 131–157.

[51] Smyj R, Wang XP, Han F. Tramadol hydrochloride. Profiles of Drug Substances, Excipients, and Related Methodology. 2013; 38: 463–494.

[52] Montero Matamala A, Bertolotti M, Contini MP, Guerrero Bayón C, Nizzardo A, Paredes Lario I, et al. Tramadol hydrochloride 75 mg/dexketoprofen 25 mg oral fixed-dose combination in moderate-to-severe acute pain: sustained analgesic effect over a 56-h period in the postoperative setting. Drugs of Today. 2017; 53: 339–347.

[53] Bravo L, Mico JA, Berrocoso E. Discovery and development of tramadol for the treatment of pain. Expert Opinion on Drug Discovery. 2017; 12: 1281–1291.

[54] Kaçmaz M, İlhan G. A comparison of the mixed and sequential use of acetaminophen and dexketoprofen in painful vaso-occlusive crises. European Journal of Clinical Pharmacology. 2024; 80: 475–480.

[55] Dhesi M, Maldonado KA, Patel P, Maani CV. Tramadol. StatPearls Publishing: Treasure Island (FL). 2025.

[56] Nikaido T, Takatsuna H, Tabata S, Shiosakai K, Nakatani T, Konno SI. Efficacy and safety of add-on mirogabalin to NSAIDs in lumbar spinal stenosis with peripheral neuropathic pain: a randomized, open-label study. Pain and Therapy. 2022; 11: 1195–1214.

[57] Zegpi C, Gonzalez C, Pinardi G, Miranda HF. The effect of opioid antagonists on synergism between dexketoprofen and tramadol. Pharmacological Research. 2009; 60: 291–295.

[58] Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Current Opinion in Anaesthesiology. 2009; 22: 588–593.

[59] Varrassi G, Hanna M, Coaccioli S, Suada M, Perrot S. DANTE study: the first randomized, double-blind, placebo and active-controlled, parallel arm group study evaluating the analgesic efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride oral fixed dose combination on moderate to severe acute pain in patients with acute low back pain-rationale and design. Pain and Therapy. 2022; 11: 1055–1070.

[60] Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. The Lancet. 2017; 389: 2338–2348.

[61] Fu JL, Perloff MD. Pharmacotherapy for spine-related pain in older adults. Drugs & Aging. 2022; 39: 523–550.

[62] Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M, et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: adjusting prescription to patient features. Biomedicine & Pharmacotherapy. 2022; 150: 112958.

[63] Shanthanna H, Ladha KS, Kehlet H, Joshi GP. Perioperative opioid administration. Anesthesiology. 2021; 134: 645–659.

[64] Zhang Q, Chan DXH, Ho KY. Efficacy and safety of fixed-dose combinations for pain in older adults. Drugs & Aging. 2024; 41: 873–879.

[65] Shenfield GM. Fixed combination drug therapy. Drugs. 1982; 23: 462–480.

[66] Varrassi G, Coaccioli S, De-Andrés J, Hanna M, Macheras G, Montero A, et al. Expert consensus on clinical use of an orally administered dexketoprofen plus tramadol fixed-dose combination in moderate-to-severe acute pain: a Delphi study. Advances in Therapy. 2019; 36: 3174–3185.

[67] Cao Z, Han K, Lu H, Illangamudalige S, Shaheed CA, Chen L, et al. Paracetamol combination therapy for back pain and osteoarthritis: a systematic review and meta-analyses. Drugs. 2024; 84: 953–967.

[68] Pergolizzi JV. Exploring the combination of gabapentinoids and opioids for postoperative analgesia. JAMA Network Open. 2020; 3: e2032139.

[69] Chen Y, Wang S, Xu S, Xu N, Zhang L, Zhou J. Current advances in neurocritical care. Journal of Intensive Medicine. 2025; 5: 23–31.

[70] Carron M, Tamburini E, Linassi F, Pettenuzzo T, Boscolo A, Navalesi P. Non-opioid analgesics and adjuvants after surgery in adults with obesity: systematic review with network meta-analysis of randomized controlled trials. Journal of Clinical Medicine. 2024; 13: 2100.

[71] Nagella AB, Yalamuru B. Genetics and gender in acute pain and perioperative opioid analgesia. Anesthesiology Clinics. 2025; 43: 127–140.

[72] Higgins GA, Allyn-Feuer A, Athey BD. Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response. Pharmacogenomics. 2015; 16: 1565–1583.

[73] Kwon C-H, Ha MW. Pharmacogenetic approach to tramadol use in the Arab population. International Journal of Molecular Sciences. 2024; 25: 8939.

[74] Chen C, Zhao Y, Tang K, Ning H, Yu X, Zhu Y, et al. Sustainable release artifact in PLGA microspheres for prolonged local aesthetics in postoperative pain management. Journal of Biomaterials Applications. 2025; 39: 714–722.

[75] Suhail M, Badshah SF, Chiu IH, Ullah A, Khan A, Ullah H, et al. A novel approach of polyvinyl alcohol/acrylic acid based hydrogels for controlled delivery of diclofenac sodium. Current Pharmaceutical Biotechnology. 2025; 26: 477–489.

[76] Uematsu M, Tamai K, Hyakutake H, Suzuki H, Tachi H, Ishikawa Y, et al. The efficacy of systemic transdermal diclofenac patch for postoperative pain after lumbar spinal surgery. Spine. 2025; 50: 201–206.

[77] Gliszczyńska A, Nowaczyk M. Lipid formulations and bioconjugation strategies for indomethacin therapeutic advances. Molecules. 2021; 26: 1576.

[78] Huang R, Yu J, Zhang B, Li X, Liu H, Wang Y. Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment. Biomaterials. 2025; 315: 122954.

[79] Boccella S, De Filippis L, Giorgio C, Brandolini L, Jones M, Novelli R, et al. Combination drug therapy for the management of chronic neuropathic pain. Biomolecules. 2023; 13: 1802.

[80] Tsui BCH, Gupta RK. Role of neuromodulation in acute pain settings. Regional Anesthesia and Pain Medicine. 2023; 48: 338–342.

[81] Shah N, Di Napoli R, Padalia D. Implantable intrathecal drug delivery system. StatPearls Publishing: Treasure Island (FL). 2025.

[82] Fattahi M, Rahimpour M, Riahi E. Opioid reward and deep brain stimulation of the lateral hypothalamic area. Vitamins and Hormones. 2025; 127: 245–281.